ArticleMolecular neurobiology2026
Gastrodin Ameliorates Pain-Depression Comorbidity through SIRT3-Dependent Alleviation of Oxidative Stress and Promotion of Mitochondrial Biogenesis.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mitochondrial Iron Handling and Lipid Peroxidation as Drivers of Ferroptosis.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropathic pain (NP) and depression frequently co-occur, creating a complex clinical challenge with limited therapeutic options due to poorly understood shared mechanisms. Our preliminary screening identified the mitochondrial deacetylase SIRT3 as a potential key regulator of this comorbidity. Building on this finding, we hypothesized that Gastrodin, a natural compound with documented neuroprotective properties, exerts its therapeutic effects by targeting SIRT3. This study was therefore designed to investigate whether Gastrodin alleviates NP-depression comorbidity through a SIRT3-dependent mechanism. A rat model of NP-depression comorbidity was established by combining spared sciatic nerve injury (SNI) with chronic unpredictable mild stress (CUMS). Behavioral tests were conducted to assess mechanical allodynia, thermal hyperalgesia, and depression-like behaviors. Molecular mechanisms were evaluated using Western blot, ELISA, qPCR, and transmission electron microscopy. The specific role of SIRT3 was confirmed using the inhibitor 3-TYP in vivo and siRNA in vitro. Gastrodin administration (200/300 mg/kg) significantly ameliorated both pain hypersensitivity and depression-like behaviors in the comorbidity model. Mechanistically, Gastrodin upregulated SIRT3 expression and enhanced its deacetylase activity in the hippocampus, as evidenced by reduced acetylation of SOD2. This led to attenuated neuroinflammation (TNF-α, IL-1β, IL-6) and oxidative stress (MDA, ROS). Furthermore, Gastrodin improved mitochondrial ultrastructure and promoted mitochondrial biogenesis via the PGC-1α/TFAM pathway in astrocytes. Critically, all therapeutic benefits of Gastrodin were abolished upon SIRT3 inhibition. Gastrodin exerts dual therapeutic effects on NP-depression comorbidity by activating the SIRT3 pathway, thereby rescuing mitochondrial function in hippocampal astrocytes. These findings identify Gastrodin as a promising candidate for treating pain-depression comorbidity and underscore SIRT3 as a critical therapeutic target.
Indexed as
Identifiers
41604013What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.